live 
WEBINAR
Clinical trial club | Novel agents for the treatment of advanced myelofibrosis
An EBAC Accredited Educational Programme
July 19, 2022
08:00 CST (15:00 CEST)
Clinical trial club | Novel agents for the treatment of advanced myelofibrosis
BOREAS trial: Navtemadlin (KRT-232) vs best available therapy in relapsed/
Myelofibrosis is associated with a significant reduction in the quality of life of patients and an increased risk of mortality. As treatment options are mainly symptomatic, major treatment goals include reduction of symptoms and improvement of quality of life. While JAK inhibitors provide spleen control and symptom improvement for patients, response to treatment is often lost and there is currently an unmet need for novel therapies to effectively target the disease at the level of the malignant stem cell.
There is an ongoing effort to develop novel approaches with different modes of action to fulfil an unmet need when JAK inhibitors are not enough or fail to halt disease progression. With such progress, it is key that healthcare professionals understand novel targets and the mechanisms of action of new agents and maintain up-to-date knowledge of the role of new agents in the therapeutic landscape.
This 60-min live webinar is brought to you by Scientific Education Support as part of the clinical trial club series entitled "Novel agents for the treatment of advanced myelofibrosis", and will take place virtually on July 19, 2022.
The aim of this webinar, chaired by Laura Michaelis, is to discuss the phase II and phase III clinical trials (NCT03662126), investigating navtemadlin in patients with myelofibrosis (MF) who relapsed on or are refractory to JAK inhibitors, with trial investigator Haifa Kathrin Al-Ali. Together, they will review results from the open-label phase II trial and consider what these findings, and the ongoing randomized controlled phase III BOREAS trial, investigating navtemadlin versus best available therapy in relapsed/refractory MF, mean for clinical practice. This webinar will provide an opportunity for participants to interact with these world-renowned speakers and hear their expert opinion on the future of clinical practice in MPN.
Agenda
This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.
Overview of the navtemadlin trials (NCT03662126)
- Phase II design
- Phase III design (BOREAS trial)
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Learning objectives
Following this event, participants will be able to:
- Describe novel therapeutic targets in MPN
- Explain the mechanisms of action of MDM2 inhibitors in MPN
- State the efficacy and safety data for navtemadlin in MPN
- Explain the role of navtemadlin in the MPN therapeutic landscape
Our speakers
Meet the experts that will be part of the clinical trial club live webinar.
Laura Michaelis
Medical College of Wisconsin
Milwaukee, US
Haifa Kathrin Al-Ali
University Hospital Halle (Saale)
Halle, DE
About the MPN Hub
The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.